Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple Myeloma

Abstract

PURPOSE We performed a retrospective chart review on 393 patients with multiple myeloma (MM) to determine the utility of the gamma gap (GG). METHODS We calculated the difference between a patient's total serum protein and albumin as a point-of-care test for assessing disease status in MM. RESULTS GG is highly correlated with the level of M-spike, and the change in GG correlates with myeloma treatment response. In addition, fitted linear models were established that allow for the calculation of M-protein level from the GG within hours from blood draw. CONCLUSION Our study has important implications in the care of MM, particularly in countries/areas with limited resources. (C) 2020 by American Society of Clinical Oncology